Holen Sie sich die Stockscreener-App
15.55
0.06%
0.01
Schlusskurs vom Vortag:
$15.54
Offen:
$15
24-Stunden-Volumen:
49,900
Relative Volume:
0.02
Marktkapitalisierung:
$16.20M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-1.13M
KGV:
-0.272
EPS:
-57.1626
Netto-Cashflow:
$-2.63M
1W Leistung:
+21.58%
1M Leistung:
+38.96%
6M Leistung:
+146.83%
1J Leistung:
-99.29%
1-Tages-Spanne:
$14.85
$15.80
1-Wochen-Bereich:
$11.60
$15.80
52-Wochen-Spanne:
$2.88
$2,550.00
Polyrizon Ltd Stock (PLRZ) Company Profile
Vergleichen Sie PLRZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
15.55 | 16.19M | 0 | -1.13M | -2.63M | -57.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Polyrizon Ltd Aktie (PLRZ) Neueste Nachrichten
Polyrizon recives Nasdaq delisting notice - MSN
Polyrizon explores investments in defense, aviation and AI sectors By Investing.com - Investing.com Nigeria
Polyrizon Ltd to explore revenue-generating investment opportunities in high-growth sectors - marketscreener.com
Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet - The Manila Times
Debt-free biotech Polyrizon hunts revenue in AI, aviation and defense - Stock Titan
Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now - TechStock²
Polyrizon Ltd. (PLRZ) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Can Polyrizon Ltd. stock rebound after recent weaknessPortfolio Gains Report & Technical Pattern Recognition Alerts - Улправда
PLRZ - Finviz
Is Polyrizon Ltd. stock undervalued vs historical averagesNew Releases Roundup & what to check before ordering - Улправда
Polyrizon names allergy blocker product NASARIX By Investing.com - Investing.com Australia
Why Polyrizon Ltd. stock is favored by top institutions2025 Winners & Losers & Fast Moving Trade Plans - Улправда
Polyrizon expects Nasarix introduction aligned with clinical progress - marketscreener.com
Polyrizon names allergy blocker product NASARIX - Investing.com
Polyrizon Brands PL-14 Intranasal Allergy Blocker as NASARIX™ - TipRanks
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™ - The Manila Times
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX - Bluefield Daily Telegraph
NASARIX: a new nasal spray brand designed to shield against allergens - Stock Titan
Polyrizon’s PL-14 shows strong pre-clinical allergen-blocking advantage over standard nasal barrier - MSN
Polyrizon announces in-vitro results for PL-16 Viral Blocker - MSN
Polyrizon stock rises after positive pre-clinical allergy blocker results By Investing.com - Investing.com Nigeria
Polyrizon stock rises after positive pre-clinical allergy blocker results - Investing.com
Polyrizon Announces Positive Data From PL-14 Allergy Blocker Formulation Study - Nasdaq
Polyrizon’s nasal allergy blocker outperforms standard in lab study By Investing.com - Investing.com South Africa
Polyrizon’s PL-14 Shows Strong Pre-Clinical Allergen-Blocking Advantage Over Standard Nasal Barrier - TipRanks
Polyrizon’s nasal allergy blocker outperforms standard in lab study - Investing.com India
Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator - The Manila Times
About Us - FinancialContent
Polyrizon submits pre-request to FDA for nasal spray against flu - Investing.com Nigeria
Polyrizon submits pre-request to FDA for nasal spray against flu By Investing.com - Investing.com South Africa
Polyrizon stock rises on FDA submission for PL-16 viral blocker - Investing.com Australia
As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated - The Manila Times
Polyrizon (PLRZ) Stock Analysis Report | Financials & Insights - Benzinga
Polyrizon reports mucoadhesion results for intranasal naloxone hydrogel - MSN
Polyrizon Ltd. to Explore Investment Opportunities in Revenue-Generating Real Assets - marketscreener.com
Polyrizon to explore investments in revenue-generating assets By Investing.com - Investing.com Nigeria
Polyrizon to pursue revenue-generating real assets while advancing intranasal biotech pipeline - MSN
Polyrizon stock rises as company explores revenue-generating investments By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Finanzdaten der Polyrizon Ltd-Aktie (PLRZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.73%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):